Sanofi Pasteur and KaloBios Pneumonia Drug Fast-Tracked

Sanofi Pasteur, the vaccines division of Sanofi , and KaloBios Pharmaceuticals announced today that the U.S. Food and Drug Administration has granted Fast Track designation to Sanofi Pasteur for the investigation of KB001A, an antibody fragment, intended for protection against bacterial pneumonia caused by Pseudomonas aeruginosa in ... (more)

http://www.drugs.com/news/sanofi-pasteur-kalobios-pneumonia-fast-tracked-44234.html?